Press Releases

Date Title View
Toggle SummaryMay 1, 2019 GenMark Diagnostics to Present at the Bank of America Merrill Lynch Health Care Conference
CARLSBAD, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the Bank of America Merrill Lynch Heath Care Conference in Las
View HTML
Toggle SummaryApril 30, 2019 GenMark Diagnostics Reports First Quarter 2019 Results
CARLSBAD, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2019 . Highlights Recognized total revenue of $21.5
View HTML
Toggle SummaryApril 30, 2019 GenMark Diagnostics Expands Commercial Team
CARLSBAD, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has expanded its commercial team in North America with the addition of Michael Harkins as Senior
View HTML
Toggle SummaryApril 15, 2019 GenMark Diagnostics Schedules First Quarter 2019 Financial Results Conference Call for April 30, 2019
CARLSBAD, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, April 30, 2019. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryApril 15, 2019 GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Negative Panel
Complete Suite of ePlex Blood Culture Identification Panels Now Available in the U.S. CARLSBAD, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received
View HTML
Toggle SummaryFebruary 21, 2019 GenMark Diagnostics Reports Fourth Quarter and Full Year 2018 Results
CARLSBAD, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2018 .
View HTML
Toggle SummaryFebruary 21, 2019 GenMark Diagnostics Announces Expansion of Executive Leadership Team
CARLSBAD, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the expansion of its executive leadership team. Effective immediately, Scott Mendel , currently GenMark's
View HTML
Toggle SummaryFebruary 20, 2019 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryFebruary 7, 2019 GenMark Diagnostics Schedules Fourth Quarter and Full Year 2018 Financial Results Conference Call for February 21, 2019
CARLSBAD, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Thursday, February 21, 2019. Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryJanuary 8, 2019 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2018
CARLSBAD, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2018 .
View HTML